Affinia Therapeutics Welcomes Rami Daoud as CFO
Affinia Therapeutics is thrilled to announce that Rami Daoud has joined the team as Chief Business and Financial Officer. With more than 25 years of rich experience in business development and corporate finance in the biopharmaceutical industry, Rami is poised to make impactful contributions to the company.
Expertise in Biopharmaceuticals
Rami Daoud is a highly regarded professional in the biopharmaceutical field, known for his strategic vision and innovative methods. He has previously held significant leadership positions at major pharmaceutical companies, including Amarin Corporation and Eli Lilly & Company. His diverse background spans multiple therapeutic areas, and he has a solid track record of successfully managing corporate strategies and financing efforts.
Leadership at Affinia
Rick Modi, the Chief Executive Officer of Affinia Therapeutics, shared his excitement about Rami's appointment, highlighting that his leadership experience and strategic acumen will be crucial as the company advances its innovative gene therapy projects. Rami's arrival comes at a pivotal moment as Affinia utilizes its state-of-the-art ART platform to tackle serious health issues by designing effective treatments aimed at rare diseases.
Commitment to Innovation
Rami is passionate about turning scientific breakthroughs into real-world solutions for patients. His vision aligns with Affinia’s mission to create rationally designed gene therapies that address significant unmet medical needs, particularly in the cardiovascular and neurological sectors. He strongly believes that effective business strategies can pave the way for the successful introduction of life-saving therapies.
Previous Experience of Rami Daoud
Prior to his role at Affinia, Rami served as the President of GeneSciences Pharmaceuticals in the USA. His time at Amarin Corporation was characterized by his ability to effectively develop corporate strategies. Additionally, Rami has held various business development roles with increasing responsibilities at companies such as Auxilium Pharmaceuticals and Human Genome Sciences. This impressive career path underscores his dedication and skill in driving strategic initiatives within the biopharmaceutical industry, making him an invaluable asset to Affinia Therapeutics.
Educational Background
Rami Daoud boasts an impressive academic background, including an M.B.A from the Wharton School and an M.S. in physiology from the University of Maryland at Baltimore. He also holds dual B.S. degrees in accounting and biology from the University of Maryland. These educational achievements further bolster his strategic decision-making capabilities in the financial and operational realms of biopharmaceutical innovation.
About Affinia Therapeutics
Affinia Therapeutics is on a mission to transform gene therapy through its unique Affinia Rationally-designed Therapeutics (ART) platform. This groundbreaking approach aims to enhance the efficacy and safety of AAV-based gene therapies by developing next-generation capsids and manufacturing processes. Affinia is committed to providing therapeutic options that significantly improve patients' lives by addressing a range of rare and prevalent diseases.
Frequently Asked Questions
What is the role of Rami Daoud at Affinia Therapeutics?
Rami Daoud has been appointed as the Chief Business and Financial Officer, where he will lead financial strategies and oversee business development initiatives.
What experience does Rami Daoud bring to Affinia Therapeutics?
Rami brings over 25 years of experience in the biopharmaceutical sector, having held senior leadership roles in corporate finance and business development across various companies.
Why is Rami Daoud's appointment significant for Affinia?
His extensive experience in strategic management and innovation in biopharma aligns perfectly with Affinia's mission to develop cutting-edge therapies, making his appointment crucial for the company's future success.
What is the mission of Affinia Therapeutics?
Affinia Therapeutics is dedicated to pioneering rationally-designed gene therapies aimed at treating rare diseases and improving the health of patients worldwide.
How does Affinia Therapeutics' ART platform work?
The ART platform focuses on enhancing the efficacy, safety, and manufacturability of gene therapies through innovative developments in capsids and promoters.
